冠福股份(002102) - 2025 Q1 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for Q1 2025 is projected to be between 190 million to 215 million CNY, representing a year-on-year increase of 240.74% to 285.57% compared to 55.76 million CNY in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is expected to be between 186 million to 210 million CNY, indicating a growth of 467.56% to 540.79% from 32.77 million CNY in the previous year [3]. - The basic earnings per share is forecasted to be between 0.0722 CNY to 0.0816 CNY, up from 0.0212 CNY in the same quarter last year [3]. - The strong performance is attributed to the good operating conditions of the wholly-owned subsidiary, which generated profits of no less than 200 million CNY from its vitamin E and pharmaceutical intermediates business [5]. Share Capital - The total share capital has been reduced to 2,632,580,490 shares following the repurchase and cancellation of 1,255,800 shares [3]. Financial Reporting - The financial data presented is a preliminary estimate by the company's finance department and has not been audited by an external auditor [7]. - Investors are advised to exercise caution and consider investment risks as the final financial data will be disclosed in the official Q1 2025 report [7].